Medindia

X

MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock

Thursday, September 20, 2007 General News J E 4
Advertisement
FT. LAUDERDALE, Fla., Sept. 19 MAKO SurgicalCorp. today announced that it has filed a registration statement on Form S-1with the U.S. Securities and Exchange Commission relating to a proposedinitial public offering of its common stock.

All of the offered shares will be sold by MAKO Surgical Corp. The numberof shares to be offered and the price range of the offering have not yet beendetermined. The Company intends to apply to have its common stock approvedfor quotation on the NASDAQ Global Market under the symbol "MAKO."

J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated will actas joint bookrunners for the offering and Cowen and Company, LLC and WachoviaCapital Markets, LLC will act as co-lead managers. The offering will be madeonly by means of a prospectus. Copies of the preliminary prospectus for theoffering, when available, may be obtained from: J.P. Morgan Securities Inc.,National Statement Processing, Prospectus Library, 4 Chase Metrotech Center,CS Level, Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley& Co. Incorporated's prospectus department at 180 Varick, New York, NY 10014,by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its advancedrobotic solution and implants for minimally invasive orthopedic kneeprocedures. MAKO's Haptic Guidance System(TM) includes an interactive hapticrobotics platform that utilizes tactile-guided robotics and patient-specificvisualization to prepare the knee joint for the insertion and alignment ofresurfacing implants through a keyhole incision. This FDA-cleared surgeon-interactive haptic robotic system allows surgeons to provide an innovativetissue-sparing bone resurfacing therapy called MAKOplasty(TM) to a large, yetunderserved patient-specific population suffering from early to mid-stageosteoarthritic knee disease. As of September 18, 2007, 80 MAKOplastyprocedures have been performed since commercial introduction in June 2006.MAKO has an intellectual property portfolio of more than two hundred licensedor owned patent applications relating to the areas of computer assistedsurgery, haptics, robotics, and implants.

A registration statement relating to these securities has been filed withthe U.S. Securities and Exchange Commission, but has not yet become effective.These securities may not be sold nor may offers to buy be accepted prior tothe time the registration statement becomes effective.

This news release shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesesecurities in any state in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such state.

SOURCE MAKO Surgical Corp.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
CuraGen Corporation Announces Appointment of Dr. T...
S
ArtJen Announces Major Clinical Trial of Its Paten...